Skip to main content

Table 1 Characteristics of participants

From: Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report

 

Control (n = 10)

Alogliptin (n = 10)

p value

Age (years)

35 ± 10

-

-

Male (%)

8 (80)

-

-

Current Smoker (%)

3(30)

-

-

HbA1c (%)

4.6 ± 0.3

-

-

BMI (kg/m2)

23.9 ± 4.1

23.9 ± 3.4

0.86

Systolic blood pressure (mmHg)

122 ± 3

121 ± 3

0.35

Diastolic blood pressure (mmHg)

71 ± 2

71 ± 2

0.99

Heart rate (beats/min)

62 ± 3

61 ± 2

0.20

Total-C (mg/dl)

185.3 ± 10.6

180.7 ± 9.9

0.58

LDL-C (mg/dl)

103.2 ± 8.9

102.2 ± 9.3

0.72

HDL-C (mg/dl)

66.3 ± 3.1

64.2 ± 3.4

0.29

TG (mg/dl)

73.7 ± 10.2

63.4 ± 7.9

0.08

RLP-C (mg/dl)

8.4 ± 1.2

6.7 ± 0.8

0.28

ApoB-48 (μg/ml)

2.5 ± 0.3

2.2 ± 0.2

0.19

Glucose (mg/dl)

93.0 ± 2.0

94.3 ± 2.1

0.54

Glucagon (pg/ml)

63.5 ± 5.4

59.4 ± 2.8

0.44

Insulin (μIU/ml)

4.8 ± 0.8

4.9 ± 1.3

0.38

HOMA-IR

1.1 ± 0.2

1.1 ± 0.3

0.51

GLP-1 (pmol/l)

3.2 ± 0.2

5.2 ± 0.7

0.03

Adiponectin (μg/ml)

9.6 ± 0.8

9.7 ± 0.7

0.31

Soluble VCAM-1 (ng/ml)

629 ± 72

606 ± 50

0.76

  1. Data are the mean ± SE or frequency counts (percentages), as appropriate. BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; RLP-C, remnant lipoprotein cholesterol; ApoB-48, apolipoprotein B-48; HOMA-IR, homeostasis model assessment of insulin resistance; GLP-1, glucagon-like peptide-1; VCAM-1, vascular cell adhesion molecule-1.